In focus · trending topic

Minerva Neurosciences

65 stories · following the connections

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

By Nasdaq OMXDec 19, 2017, 1:01 PM UTC

Minerva Neurosciences Names Richard Russell President

By Nasdaq OMXDec 11, 2017, 9:30 PM UTC

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

By Nasdaq OMXDec 11, 2017, 1:15 PM UTC

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

By Nasdaq OMXDec 6, 2017, 1:30 PM UTC

Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017

By Nasdaq OMXNov 8, 2017, 2:00 PM UTC

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

By Nasdaq OMXNov 6, 2017, 12:30 PM UTC

Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy

By Nasdaq OMXOct 31, 2017, 12:00 PM UTC

Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017

By Nasdaq OMXOct 30, 2017, 12:30 PM UTC